The number of people with susceptibility test result for rifampicin in Australia
Australia: The number of people with susceptibility test result for rifampicin was 83.5 in 2021. ▼ Falling
Latest (2021)
83.5
Change on year
down 11.3%
World rank
90th
of 146 countries
All-time high
94.11
in 2020
All-time low
83.5
in 2021
Years of data
5
2017–2021
The number of people with susceptibility test result for rifampicin in Australia, 2017–2021
Source: World Health Organization, Global Health Observatory.
Analysis
Australia recorded 83.5 for the number of people with susceptibility test result for rifampicin in 2021. That is the lowest value across all 5 years on record.
The figure is down 11.3% on the previous year and down 9.6% over five years.
Australia ranks 90th of 146 countries on this measure, in the middle of the range.
The number of people with susceptibility test result for rifampicin in Australia, year by year
| Year | Value | Change |
|---|---|---|
| 2017 | 92.35 | — |
| 2018 | 93.32 | +1.0% |
| 2019 | 92.19 | -1.2% |
| 2020 | 94.11 | +2.1% |
| 2021 | 83.5 | -11.3% |
Australia compared with similar countries
- Australia's 83.5 is below the median for high income countries, which is 92.6, 90% of the median. (56 countries reporting)
- Australia's 83.5 is below the median for East Asia & Pacific, which is 96.47, 87% of the median. (28 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 92.62 | 92.19 | 93.32 | 3 |
| 2020s | 88.8 | 83.5 | 94.11 | 2 |
Countries ranked near Australia
More health data for Australia
- Un projection of annual infant deaths, annual growth rate -1.83 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.9072 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 906.6 deaths per 1,000 people (2090)
- Number of infants who die before age 1 215 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2021)
- Population ages 00-04, female, annual growth rate 1.45 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0279 units per person (2025)
- Population ages 00-04, male, annual growth rate 1.35 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is the number of people with susceptibility test result for rifampicin in Australia?
- The number of people with susceptibility test result for rifampicin in Australia was 83.5 in 2021, according to World Health Organization, Global Health Observatory.
- What is the highest the number of people with susceptibility test result for rifampicin recorded in Australia?
- The highest recorded value was 94.11 in 2020.
- What is the lowest the number of people with susceptibility test result for rifampicin recorded in Australia?
- The lowest recorded value was 83.5 in 2021.
- How does Australia rank for the number of people with susceptibility test result for rifampicin?
- Australia ranks 90th out of 146 countries with data for 2021.
- Where does this Australia data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 5 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).